Phil B.FontanarosaMD, Deputy EditorIndividualAuthorStephen J.LurieMD, PhD, Fishbein FellowIndividualAuthor
Copyright 2000 American Medical Association. All Rights Reserved.
Applicable FARS/DFARS Restrictions Apply to Government Use.2000
To the Editor: The article by Dr Davidson and
colleagues1 and the Editorial by Dr Vinicor2 bring attention to the increasing importance of
the glycosylated hemoglobin (HbA1C) in the diagnosis and therapy
of glucose intolerance and of diabetes mellitus. To simplify the complex approach
of Davidson et al, one may say that HbA1C, which is a surrogate
test for glycosylation of proteins throughout the body, should be the arbitrator
test when a high-sensitivity screening test with a known false-positive rate
is used. Vinicor takes a more conservative approach because not all complications
of diabetes can be associated with HbA1C results.
Saunders AM. Glycosylated Hemoglobin as a Diagnostic Test for Type 2 Diabetes Mellitus. JAMA. 2000;283(5):605-607. doi:10.1001/jama.283.5.601